# Kelly Holman

> Kelly Holman is a startup investor at Genesys Capital. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Genesys Capital](https://shizune.co/investors/profile/genesys-capital)
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/kelly-holman/43/58/207

Kelly Holman is a startup investor at Genesys Capital. Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $225 million of venture capital and has been instrumental in deploying over $140 million across 28investments. He currently serves on the Board of Directors of Functional Neuromodulation Ltd. and ImpoPharma Inc. From 2001 to 2013, he served on the board of Epocal, a Genesys portfolio company recently acquired by Alere (NYSE: ALR). Mr. Holman is active in deal origination and company creation and has advised Canada's National Biotechnology Advisory Committee on strategies for financing start-up and early-stage biotechnology companies.Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corp. During his tenure at MDS, he was involved in all stages of investment from start-up and early-stage to mezzanine stage and public company investing.Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer's disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.

## About Genesys Capital

VC Fund · Toronto, Canada

Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising biotechnology investment opportunities.

5 contacts available at Genesys Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Damian Lamb | Co-Founder and Managing Director | https://shizune.co/investors/profile/damian-lamb |
| Jamie Stiff | Managing Director | https://shizune.co/investors/profile/jamie-stiff |
| Jennifer Williams | Partner and CFO; Director of Finance and Operations | https://shizune.co/investors/profile/jennifer-williams |
| Kelly Holman | Co-Founder and Managing Director | https://shizune.co/investors/profile/kelly-holman |
| Maxime Ranger | Venture Partner | https://shizune.co/investors/profile/maxime-ranger |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co